Business Context and Reporting Period
This Form 8-K was filed by MEI Pharma, Inc. (trading symbol: MEIP) on April 13, 2020. The filing reports the entry into a new global License, Development and Commercialization Agreement with Kyowa Kirin Co., Ltd. (KKC) regarding the company's lead product candidate, ME-401. This new agreement replaces and expands upon a prior Japan-specific agreement dated October 31, 2018.
Key Financial Metrics and Transaction Terms
The filing details a significant commercial transaction rather than periodic financial results. Key financial terms include:
- Upfront Payment: KKC will pay MEI Pharma an initial payment of $100 million within 30 days of invoice receipt.
- Milestone Payments: MEI Pharma may earn up to approximately $582.5 million in potential development and commercialization milestones.
- Royalties: MEI Pharma is entitled to tiered royalties on net sales of ME-401 in regions outside the United States (Ex-US), beginning in the teens.
- Revenue Sharing: In the U.S., MEI Pharma will book all revenue from sales. U.S. profits and costs (including development) will be shared on a 50-50 basis between MEI Pharma and KKC.
- Cost Allocation: KKC is solely responsible for all costs related to development and commercialization in the Ex-US.
The filing does not provide current revenue, profit, cash flow, or debt figures for the company.
Material Changes Versus Prior Period
The primary material change is the termination of the October 31, 2018, Japan-specific agreement and its replacement with a global collaboration. Under the new terms:
- Scope Expansion: The collaboration now covers global development, manufacturing, and commercialization of ME-401, rather than being limited to Japan.
- Licensing Structure: MEI Pharma grants KKC a co-exclusive license for the U.S. and an exclusive license for the Ex-US. KKC grants MEI Pharma a co-exclusive license for the U.S. and a royalty-free license for Ex-US obligations.
- Operational Roles: KKC will lead Ex-US activities, while both parties will co-develop and co-promote in the U.S.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The agreement establishes a joint steering committee to manage the collaboration. The term continues until the latest of patent expiration, regulatory exclusivity expiration, or ten years after the first commercial sale in a specific country.
Risks and Contingencies:
- COVID-19 Impact: The filing includes a supplemental risk factor regarding the global pandemic. Potential adverse impacts include delays in clinical trials, patient enrollment difficulties, supply chain disruptions, and reduced productivity due to work-from-home policies.
- Capital Markets: The company notes that stock prices in the biopharmaceutical sector have been volatile due to the pandemic, which could affect the ability to raise capital on favorable terms.
- Termination Rights: KKC retains the right to terminate the agreement for convenience. The agreement also outlines specific termination triggers related to material breaches, bankruptcy, or failure to make the upfront payment.
Investor Verification Checklist
- Verify the receipt of the $100 million upfront payment from Kyowa Kirin Co., Ltd.
- Monitor the status of ME-401 clinical trials for delays attributed to the COVID-19 pandemic.
- Review the full text of the License, Development and Commercialization Agreement (to be filed as an exhibit to the 10-K) for confidential terms and specific milestone definitions.
- Assess the company's cash runway and liquidity position following the receipt of the upfront payment.
- Track the establishment and output of the joint steering committee.